Table 2.

Symptom severity, functional deficits, and clinical findings.

	No neuP	Mild neuP	Mod/sev neuP	P
Symptom severity, median [IQR]
Boston Symptom Scale	2.1 [1.1]‡	2.4 [0.9]§	3.2 [0.9]	<0.0001#
NPSI total	10.0 [17.5]‡	16.0 [15.8]§	38.5 [20.8]	<0.0001#
NPSI burning	0.0 [0.0]‡	0.0 [4.0]	2.0 [6.0]	0.001#
NPSI deep	0.0 [2.1]	0.0 [2.0]§	2.5 [4.0]	0.007#
NPSI paroxysmal	0.0 [0.1]‡	0.0 [2.1]§	3.0 [4.0]	<0.0001#
NPSI evoked	0.0 [0.1]	0.0 [2.0]§	2.7 [3.7]	<0.0001#
NPSI paraesthesia	3.5 [3.1]‡	5.3 [5.5]§	7.0 [4.3]	<0.0001#
Functional deficits, median [IQR]
Boston Function Scale	1.6 [0.9]‡	1.9 [0.9]	2.6 [1.4]	0.004#
Symptom distribution, n (%)
Extramedian spread	10 (46)	19 (35)§	21 (66)	0.024*
Proximal spread	11 (50)	31 (57)	23 (72)	0.229*
Clinical examination, n (%) abnormal
Light touch	1 (5)‡	30 (56)	16 (50)	0.004†
Pinprick	6 (27)‡	38 (72)	19 (59)	<0.0001*
Phalen test	13 (62)	37 (82)	24 (80)	0.169*
Tinel sign	7 (33)	23 (46)	20 (67)	0.050*
Compression sign	8 (38)	27 (55)	13 (43)	0.354*
Muscle strength‖
MRC3	0 (0)	0 (0)	1 (4)
MRC4	3 (20)	12 (30)	5 (20)	0.617†
MRC5	12 (80)	29 (71)	19 (76)
Thenar wasting	6 (29)	19 (35)	7 (22)	0.423*

Data are shown as median [IQR] or n (%)

^*P values reflect χ² associations. #P values reflect Kruskal Wallis results.

^†P values reflect Fisher exact test associations.Significant overall comparisons are highlighted in bold.

^‡Significant Bonferroni-adjusted Helmert contrasts are indicated for no neuP vs combined neuP groups.

^§Significant Bonferroni-adjusted Helmert contrasts are indicated for mild vs moderate/severe neuP groups.

^‖Data for 27 patients not recorded.

IQR, interquartile range; MRC, Medical Research Council Muscle Strength Scale; neuP, neuropathic pain; NPSI, Neuropathic Pain Symptom Inventory.